NO20092743L - Antistoffer mot CD200R - Google Patents

Antistoffer mot CD200R

Info

Publication number: NO20092743L
Authority: NO; Norway
Prior art keywords: antibodies; cd200r; relates; human inhibitory; inhibitory cd200r
Prior art date: 2006-12-22

Application number

NO20092743A

Other languages

English (en)

Norwegian (no)

Inventor

Leonard G Presta

Holly M Cherwinski

Joseph H Phillips

Original Assignee

Schering Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2006-12-22

Filing date

2009-07-21

Publication date

2009-09-21

2009-07-21 Application filed by Schering Corp filed Critical Schering Corp

2009-09-21 Publication of NO20092743L publication Critical patent/NO20092743L/no

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Immunology (AREA)
Animal Behavior & Ethology (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Pulmonology (AREA)
Rheumatology (AREA)
Physical Education & Sports Medicine (AREA)
Orthopedic Medicine & Surgery (AREA)
Gastroenterology & Hepatology (AREA)
Dermatology (AREA)
Pain & Pain Management (AREA)
Cell Biology (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Ophthalmology & Optometry (AREA)
Transplantation (AREA)
Microbiology (AREA)
Mycology (AREA)
Epidemiology (AREA)
Neurosurgery (AREA)
Toxicology (AREA)
Zoology (AREA)
Peptides Or Proteins (AREA)

NO20092743A 2006-12-22 2009-07-21 Antistoffer mot CD200R NO20092743L (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US87661806P	2006-12-22	2006-12-22
PCT/US2007/026202 WO2008079352A2 (en)	2006-12-22	2007-12-20	Antibodies to cd200r

Publications (1)

Publication Number	Publication Date
NO20092743L true NO20092743L (no)	2009-09-21

Family

ID=39563108

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20092743A NO20092743L (no)	2006-12-22	2009-07-21	Antistoffer mot CD200R

Country Status (14)

Country	Link
US (1)	US8212008B2 (pt)
EP (1)	EP2121760A2 (pt)
JP (1)	JP2010512791A (pt)
KR (1)	KR20090094846A (pt)
CN (1)	CN101679519A (pt)
AR (1)	AR064610A1 (pt)
AU (1)	AU2007338670A1 (pt)
BR (1)	BRPI0720841A2 (pt)
CA (1)	CA2673282A1 (pt)
IL (1)	IL199446A0 (pt)
MX (1)	MX2009006879A (pt)
NO (1)	NO20092743L (pt)
SG (1)	SG191442A1 (pt)
WO (1)	WO2008079352A2 (pt)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP2336321A1 (en) *	1999-05-13	2011-06-22	Medical Research Council	Ox2 receptor homolog
US9079957B2 (en)	2009-04-16	2015-07-14	The University Of Tokyo	Diagnosis and treatment of cancer using anti-TMPRSS11E antibody
EP2589609A1 (en) *	2011-11-03	2013-05-08	Pierre Fabre Medicament	Antigen binding protein and its use as addressing product for the treatment of cancer
PL3489261T3 (pl)	2012-08-24	2021-08-16	The Regents Of The University Of California	Przeciwciała i szczepionki do stosowania w leczeniu nowotworów z ekspresją ROR1 i w hamowaniu przerzutu
WO2015057906A1 (en) *	2013-10-16	2015-04-23	Janssen Biotech, Inc.	Cd200 receptor 1 agonists
CN110922481A (zh)	2015-09-24	2020-03-27	第一三共株式会社	抗garp抗体
KR20230047507A (ko)	2016-06-27	2023-04-07	더 리젠츠 오브 더 유니버시티 오브 캘리포니아	암 치료 조합
TWI749367B (zh) *	2018-09-14	2021-12-11	美商美國禮來大藥廠	Cd200r促效劑抗體及其用途
WO2021096753A1 (en)	2019-11-12	2021-05-20	Eli Lilly And Company	Cd200 receptor antagonist binding molecules
PE20230460A1 (es) *	2020-05-29	2023-03-10	23Andme Inc	Anticuerpos anti-cd200r1 y metodos de uso de estos
WO2022036116A1 (en) *	2020-08-14	2022-02-17	The Board Of Trustees Of The Leland Stanford Junior University	Cd200 blockade to increase the anti-tumor activity of cytotoxic t cells
WO2023196866A1 (en) *	2022-04-06	2023-10-12	Mirobio Limited	Engineered cd200r antibodies and uses thereof
US20250313626A1 (en) *	2022-05-19	2025-10-09	Harbour Biomed (Shanghai) Co., Ltd.	Anti-cd200r1 antibodies

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5859205A (en) *	1989-12-21	1999-01-12	Celltech Limited	Humanised antibodies
EP2336321A1 (en)	1999-05-13	2011-06-22	Medical Research Council	Ox2 receptor homolog
US20030223991A1 (en) *	2002-03-15	2003-12-04	Cherwinski Holly M.	Methods of modulating CD200 receptors
SI1501369T1 (sl) *	2002-04-26	2015-10-30	Genentech, Inc.	Neafinitetno čiščenje proteinov
PE20090047A1 (es)	2003-11-10	2009-01-26	Schering Corp	Anticuerpo recombinante humanizado anti-interleuquina 10

2007
- 2007-12-20 BR BRPI0720841-3A2A patent/BRPI0720841A2/pt not_active Application Discontinuation
- 2007-12-20 CA CA002673282A patent/CA2673282A1/en not_active Abandoned
- 2007-12-20 SG SG2011094760A patent/SG191442A1/en unknown
- 2007-12-20 AU AU2007338670A patent/AU2007338670A1/en not_active Abandoned
- 2007-12-20 AR ARP070105775A patent/AR064610A1/es unknown
- 2007-12-20 WO PCT/US2007/026202 patent/WO2008079352A2/en not_active Ceased
- 2007-12-20 CN CN200780051592A patent/CN101679519A/zh active Pending
- 2007-12-20 KR KR1020097015014A patent/KR20090094846A/ko not_active Withdrawn
- 2007-12-20 US US12/520,033 patent/US8212008B2/en not_active Expired - Fee Related
- 2007-12-20 JP JP2009542944A patent/JP2010512791A/ja active Pending
- 2007-12-20 MX MX2009006879A patent/MX2009006879A/es not_active Application Discontinuation
- 2007-12-20 EP EP07867958A patent/EP2121760A2/en not_active Withdrawn
2009
- 2009-06-18 IL IL199446A patent/IL199446A0/en unknown
- 2009-07-21 NO NO20092743A patent/NO20092743L/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
EP2121760A2 (en)	2009-11-25
KR20090094846A (ko)	2009-09-08
US8212008B2 (en)	2012-07-03
AR064610A1 (es)	2009-04-15
WO2008079352A3 (en)	2009-03-19
AU2007338670A2 (en)	2009-10-01
JP2010512791A (ja)	2010-04-30
WO2008079352A2 (en)	2008-07-03
SG191442A1 (en)	2013-07-31
CA2673282A1 (en)	2008-07-03
BRPI0720841A2 (pt)	2014-03-04
AU2007338670A1 (en)	2008-07-03
US20100178296A1 (en)	2010-07-15
MX2009006879A (es)	2009-07-03
CN101679519A (zh)	2010-03-24
IL199446A0 (en)	2010-03-28

Legal Events

Date	Code	Title	Description
2013-07-29	FC2A	Withdrawal, rejection or dismissal of laid open patent application

Publication	Publication Date	Title
MX2009006879A (es)	2009-07-03	Anticuerpos contra el cd200r.
NO20092652L (no)	2009-09-11	Konstruert anti-TSLP-antistoff
IN2012DN00863A (pt)	2015-07-10
LT3597216T (lt)	2022-11-10	Žmogaus antikūnai, kurie riša limfocito aktyvavimo geną-3 (lag-3) ir jų naudojimas
MA32982B1 (fr)	2012-01-02	Proteines de liaison au recepteur cgrp humain
MX2010004219A (es)	2010-08-09	Agentes de enlace de cd19 y usos de los mismos.
PH12015500248A1 (en)	2018-06-25	Humanized anti-cxcr5 antibodies, derivatives thereof and their uses
MEP35408A (en)	2011-02-10	Tweak binding antibodies
EA201000844A1 (ru)	2011-10-31	Связывающие wise агенты и эпитопы
EA200900781A1 (ru)	2009-12-30	4-фенилпиран-3,5-дионы, 4-фенилтиопиран-3,5-дионы и циклогексантрионы, как новые гербициды
MX2010008688A (es)	2010-08-30	Anticuerpos anti-receptor de linfopoyetina estromal timica procesados por ingenieria.
DK2215119T3 (da)	2013-02-04	Monoklonale antistoffer der binder til HGM-CSF og medicinske sammensætninger omfattende de samme.
LTPA2016030I1 (lt)	2016-11-10	Dauginės mielomos, naudojant kombinuotas terapijas, pagrįstas anti-CS1 antikūnais, gydymo būdai
CY2016023I2 (el)	2017-04-26	Πρωτεϊνες συνδεσης αντιγονου προς προπρωτεϊνη κονβερτασης σουμπτιλισινης κεχιν τυπου 9 (pcsk9)
BRPI0817250A2 (pt)	2014-06-17	Anticorpo anti-receptor da il-6.
CR20120210A (es)	2012-07-20	Proteínas de enlace al antigeno il-23 humanas
CY1117942T1 (el)	2017-05-17	Αντισωματα προσδεματος επαγωγης πολλαπλασιασμου (april)
GB2437009A (en)	2007-10-10	Ranking system
BRPI0818865A2 (pt)	2015-05-05	Anticorpos monoclonais contra proteína c ativada.
MY177564A (en)	2020-09-20	Anti-nr10 antibody and use thereof
EA201000717A1 (ru)	2010-12-30	Молекулы и способы, предназначенные для модуляции компонента системы комплемента
MA38498A1 (fr)	2017-07-31	Protéines de liaison anti-lag-3
EA201270662A1 (ru)	2013-01-30	Связывающие элементы для человеческого цитамегаловируса
NO20091181L (no)	2009-05-18	Anti-C5AR-antistoffer med forbedrede egenskaper
NO20083593L (no)	2008-10-17	Anti-EphrinB2-antistoffer og fremgangsmater for anvendelse av disse